期刊文献+

卡维地洛治疗慢性充血性心力衰竭57例疗效观察

Clin Ical Effects of Carvedilol on Patients with Chronic Congestive Heart Fallure
下载PDF
导出
摘要 目的观察卡维地洛治疗慢性充血性心力衰竭(CHF)的疗效。方法将112例CHF病人随机分为治疗组(57例)和对照组(55例),对照组应用利尿剂、血管紧张素转换酶抑制剂(ACEI)、洋地黄类、硝酸酯类等治疗;治疗组在对照组治疗基础上应用卡维地洛,起始剂量为3.125 mg,1次/d,口服,1周后剂量加倍,最大剂量为12.5 mg,2次/d,6个月后进行疗效比较。结果卡维地洛治疗组患者的心功能、心率、左室射血分数(LVEF)、左室舒张末内径(LVEDD),6 min步行距离与对照组相比,均有显著性差异(P<0.01)。结论CHF患者在应用利尿剂、ACEI和洋地黄类治疗的基础上加用卡维地洛可取得更好的疗效,可明显改善心功能和运动耐量。 Objective To investigate the clinical effect of Carvedilol on patientswith Congestive HearFail- ure (CHF). Methods 112 atients with CHF were randomly divided into Carvedilol observational group and control group. All the 112 patitnets were given angiotensin converting enzyme inhibitor (ACEI), diuretics, digitalis and nitricacid ester. Carvedilol was taken orally in observationalgroup in addition. Initial dosage was 3. 125 rag,once perday. One week later, the dosagewas doubled with maximum of 12.5 rng & twice per day.The curative effect was observed after a period of six - month treatment. Results There were significant differences in the improvement of cardiac function, heart rate, leftventricle ejection fraction (LVEF), 6minute walking test, in observational group as compared with control group ( P 〈 0.01). Concluion Better curative effectwillbe achieved on CHF patientswho take Carvedilol in addition than those who only take (ACEI),diuretics & digitalis,It could improve cardiac function and long-term outcome.
作者 陈日健
出处 《黑龙江医学》 2007年第8期586-588,共3页 Heilongjiang Medical Journal
关键词 卡维地洛 心力衰竭 充血性 Carvedilol Heart failure Congestive
  • 相关文献

参考文献9

二级参考文献28

  • 1[1]Rigger AJ. Neuroendocrine excitation in heart failure. Br Heart J, 1994, 72(2suppl):s28
  • 2[2]Lysko PG, Lysko KA, Webb CL et al. Neuroprotective of Carvedilol and a Hydroxylated Derivative. Biochemical Pharm, 1998, 56:1645
  • 3[3]Feuerstein GZ, Bril A, Ruffolo RR et al. Protective effect of Carvedilol in the myocardium. Am J Cardio, 1997, 80(11A):41L
  • 4[4]Fisher LD, et al. Carvedilol and the Food and Durg Administrition approval process: an introduction. Control Clin Trials, 1999, 20(1):1
  • 5[5]Dupont AG. Effects of carvedilol on renal fuction. Eur J Clin Pharmacol, 1990, 38(2 suppl):s96
  • 6[6]Gellai M, DeWolf R, Ruffolo RR Jr et al. Effects of carvedilol on renal hemodynamics and renal excretory function in spontaneously hypertentive rats. Pharmacology, 1990,41:200
  • 7[7]Ruffolo RR Jr, Feuerstein GZ, Ohlstein EH et al. Recent observations with β-adrenoceptor blockade. Am J Hyper, 1998, 11:9s
  • 8Cleland JG, Clark A. Has the survival of the heart failure population changed? Lessons from trials. Am J Cardiol, 1999,83:112D-119D.
  • 9Massie BM, Shah NB. Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management. Am Heart J, 1997,133:703-712.
  • 10Gary R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA, 1995,273:1450-1456.

共引文献256

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部